Abstract Esthesioneuroblastoma (ENB) is derived from the specialized olfactory neuroepithelium. Hyams grading and Kadish staging have been used to prognosticate and to guide treatment decisions. In this study, we sought to validate the prognostic utility of these systems in a large ENB cohort. We retrospectively analyzed the records of patients with ENB who had been evaluated and treated at our institution. The association of grade and stage with prognostic outcome was assessed; the Kaplan-Meier estimator was used to generate 5-year OS and DFS curves. Out of 124 cases we identified, 121 were assessed for grading and 109 for staging. Review of the tissue samples revealed that 62 % of tumors were low grade (I/II) and 21 % were high grade (III/IV); 17 % of tumors were metastasis. The OS rate was 75 % at 5 years. The DFS was 60 % at 5 years. The OS was significantly worse for metastatic ENB (low-grade ENB vs metastatic ENB p = 0.01598); the DFS was significantly worse for high grade versus low grade ENB. Of the 109 cases that had been staged, 16 % were stage A, 33 % stage B, 43 % stage C, and 8 % stage D. In the A, B, and C groups, there were no significant differences between recurrence, distant metastasis, or 5-year survival rates. Statistical significance was not reached with the T, N, M and overall staging system. Age cutoff of 65 years reliably predicted OS. High grade of ENB was significantly associated with poor outcome, while advanced stage was not associated with poor outcome in this large cohort. Grading should certainly be considered in prognostication and treatment decisions for ENB.
Introduction
Esthesioneuroblastoma (ENB) is thought to arise from olfactory neuroepithelium, which originates at the olfactory placodes and in adults is replaced partially by respiratory mucosa. First described by Berger, Luc, and Richard in 1924, ENB has been characterized as a rare malignant neoplasm of the sinonasal cavity that arises in the superior portion of the nasal vault [1] [2] [3] [4] . A variety of nomenclature has been used to describe this tumor (esthesioneuroblastoma, esthesioneuroepithelioma, esthesioneurocytoma, olfactory neuroblastoma (ON), and neuroendocrine carcinoma [4, 5] ); the accepted terms at this time are esthesioneuroblastoma and olfactory neuroblastoma. Phenotypically, ENB is intermediate between that of a pure neural neoplasm (e.g., neuroblastoma and paraganglioma) and a neuroendocrine epithelial tumor (e.g., carcinoid, neuroendocrine carcinoma, small cell carcinoma) [5] . Due to variation in healthcare practices, resources, and departmental structure of surgical and pathology practices worldwide, currently ENB may be diagnosed individually or jointly by a general surgical pathologist, a head and neck pathologist, or by a neuropathologist each of whom might use slightly different terminology, as illustrated by the respective ENB descriptions in the two corresponding WHO tumor classifications [2, 4, 5] .
The olfactory epithelium is unique in the human nervous system in that it is capable of regeneration. The histologic organization of the olfactory organ reflects this ability. Several cell types are present in the olfactory epithelium: mature olfactory neuroepithelial cells, a basal layer of stem cells that repopulate the differentiated epithelium, sustentacular supporting cells, and flat cells forming the ducts of Bowman in the olfactory lamina propria [6] [7] [8] . These cell types are closely related and seem to be at least partly generated from a common progenitor cell during recovery after epithelial injury. The anatomic distribution of ENB is confined to the cribriform plate, the superior turbinate, and the superior third of the nasal septum. Rare cases of ''ectopic'' ENB have been reported for the nasopharynx, maxillary sinus, ethmoid sinus, and inferior meatus of nasal cavity entirely intracranial or in the sella turcica. ENB with no involvement of the cribriform plate should be a diagnosis of exclusion for ENB [2] . The differential diagnosis is broad: ENB can be confused histologically with several other ''small blue round cell tumors'' of the nasal cavity and paranasal sinuses [1, 2, 9] . Tumors commonly confused with ENB include sinonasal undifferentiated carcinoma, sinonasal neuroendocrine carcinoma, small cell carcinoma, pituitary adenoma, melanoma, lymphoma, and rhabdomyosarcoma. Therefore, thorough pathologic review and ancillary studies are essential to differentiating between these tumor types and properly diagnosing ENB.
Several factors make the characterization and treatment of ENB challenging. First the tumor is very rare, accounting for approximately 2 % of all malignant sinonasal tumors. Second, the tumor can be difficult to differentiate from several other neoplasms. Third, ENB itself can have variable biological activity, ranging from relatively indolent to both locally aggressive and metastatic.
The only histological grading system available for ENB was proposed by Hyams in 1988 on the basis of the Armed Forces Institute of Pathology experience [9] . This system categorizes each case of ENB into one of four grades, ranging from well differentiated (I) to least differentiated (IV), based on the tumor architecture, cellular pleomorphism, presence of neurofibrillary matrix and rosettes, mitotic activity, and presence of necrosis or calcifications.
The clinical staging system of ENBs was introduced by Kadish et al. [10] . In this study, however, it is uncertain the spectrum of histologic grading in the tumors, based on their descriptive criteria. This system was revised 17 years later by Morita et al. [11] to include a description of stage D tumors (consisting of cervical or distant metastases) and has been shown to be a good predictor of outcomes [12] [13] [14] [15] . The optimal treatment of ENB is controversial. Surgery followed by radiotherapy is considered by most treatment centers as the gold standard for management. The usefulness of neoadjuvant or adjuvant chemotherapy remains unknown, and the relevance of regional lymph node dissection or radiotherapy is controversial. Both the Hyams grading and Kadish staging systems have been used to guide treatment decisions, including the appropriate use of neoadjuvant or adjuvant therapies. This has resulted in conflicting results between institutional case series and thus to different treatment recommendations.
In our retrospective study, we aimed to validate the prognostic ability of these grading and staging systems with a large cohort of ENB patients at our institution.
Materials and Methods

Patient Population and Data Collection
This retrospective single-institution study was approved by the Institutional Review Board. All medical reports of patients treated for or diagnosed with ENB at the institution between January 1990 and June 2013 were reviewed for clinical data: age, sex, risk factors, tumor stage, surgical management, post-operative treatment (radiotherapy including fields, and chemotherapy including regimens), recurrence, metastasis, and survival data. Cases with missing clinical data or unavailable material for histopathological reassessment were excluded from this study.
Histopathological Evaluation
The available hematoxylin-and eosin-stained slides of the patients in our cohort were reviewed by a dedicated head and neck pathologist (DB) expert in sinonasal neoplasia who was unaware of the clinical outcome, and the lesions were scored according to the Hyams grading system. This system is neither binary (? or -) nor quantitative. The ENBs were classified using a mixed grading system that took into account the most common Hyams features. Occasional cases may show features that fall into both low-grade and high-grade categories. Grade III/IV was assigned to tumors morphologically recognizable as ENB, which had some but not all the criteria required to be classified as grade IV and could not be classified as pure grade III. The same algorithm was used for grade II/III. The presence of cellular pleomorphism, necrosis, and brisk mitotic activity override the presence of nested architecture and neurofibrillary matrix or rosettes. Because it is easier to use and generates similar results, we used a 2-tiered ENB grading system: low grade (I/II) ( Fig. 1 ) and high grade (III/IV) (Fig. 2) . Immunohistochemical analysis was performed, with a screening panel that included keratin cocktail, synaptophysin, S100, melanoma cocktail, and desmin, on all cases (either diagnostic biopsy or resection) in order to establish/confirm the ENB diagnosis.
Statistical Analysis
Descriptive statistics for scaled values and frequencies of study patients within the categories for each of the parameters of interest were enumerated with the assistance of commercial statistical software. Curves describing overall and disease-free survival of patients were generated by the Kaplan-Meier product limit method. The statistical significance of differences between the actuarial curves was tested by the log rank test. Follow-up time was the time from first appointment at the University of Texas M. D. Anderson Cancer Center for the primary tumor of concern until the date of last contact or death for survival measurements. For disease-free survival plots, the starting point was the end of treatment for the original disease and the endpoint The 5 and 10 years overall survival was 75 and 55 % respectively, while the disease free survival was 60 and 40 % respectively (Fig. 4a, b) . Distant metastasis was not significantly associated with histological grade (9 and 7 % in low-grade and high-grade tumors, respectively). Recurrence was less common in low-grade ENB than in highgrade ENB (23 vs. 12.5 %). Kaplan-Meier analysis revealed that the overall survival was significantly worse for metastatic ENB (low-grade ENB vs metastatic ENB p = 0.01598) (Fig. 5a) ; the disease free survival was significantly worse for high grade versus low grade ENB (low-grade vs high-grade ENB p = 0.04551; low-grade ENB vs metastatic ENB p = 0.03673) (Fig. 5b). e. Association between tumor stage and prognosis, treatment, and outcomes
In the A, B, C and D groups, there were no significant differences between recurrence, distant metastasis, or 5-year survival rates (Fig. 6) . Statistical significance was neither reached with T, N, M or overall staging system. Age cutoff of 65 years reliably predicted OS (p = 0.03944) (Fig. 7) .
Discussion
The diagnosis and management of ENB have improved significantly in the last three decades, yet several important questions remain unanswered. As the recurrence patterns of this disease are better described with long-term studies using large patient sets, it will become more clear which staging and grading systems are most accurate and useful for guiding treatment and for prognostication [4] .
Both the Hyams grading system and the Kadish staging system have been used to provide a prognosis for ENB patients and to help guide treatment decisions, including the appropriate use of neoadjuvant or adjuvant therapies. The Hyams grading scheme captures the spectrum of ENB maturation. Several groups have asserted that grade III and more predominantly grade IV ENBs are in fact sinonasal undifferentiated carcinomas (SNUCs). The main differential diagnosis is between high-grade ENB and SNUC, which has clinical relevance because SNUC is considered to have a much worse prognosis than ENB. We have validated the findings from our systematic review with a detailed dataset collected retrospectively from our institution. To our knowledge, the current study is the largest cohort of ENB patients to date from a single institution that has been reported in the literature, and the largest series for which the Hyam's grading scale has been applied to evaluate the association with patient outcome.
In an analysis of survival and prognostic factors, Jethanamest et al. [16] applied the modified Kadish staging system to 261 cases of ENB from the SEER database. Cox regression analysis results showed that the staging system was a significant predictor of disease-specific survival [16] . The influence of the Hyams grading system is controversial and yet to be fully understood. A recent large study from the Mayo Clinic concluded that the extent of involvement at presentation (Kadish stage and lymph node metastasis) and a higher Hyams grade were the two factors that appeared to have the greatest impact on prognosis [17] . That retrospective single-institution study included 109 patients, 87 of whom had histological information available for analysis. Dulguerov reported in 1992 a 5-year survival rate of 74 % [14] . In the Mayo Clinic review, Hyams grades were as follows: grade I 6 %, grade II 48 %, grade III 37 %, grade IV 9 %; for multivariate analysis, grade I and IV were included with grade II and III-low and high grade respectively. The Mayo results for low-grade tumors (54 %) are similar to those found at MDACC (62 %), however the Mayo series reported a higher number of high grade lesions (46 % Mayo compared to 21 % MDACC). The cohort at Mayo included 87 patients with available pathology slides, versus 121 in MDACC study, however here 21 patients (17 %) presented with cervical lymph node metastasis, with primary tumor resected elsewhere and/or not available for pathologic grading. The Mayo series also reached statistical significance for Hyams low and high grade (p = 0.04, and Hyams 4 had a particularly poor outcome p \ 0.001); this outcome was very close to MDACC's (p = 0.004). In our review, grade III/IV was assigned to tumors that were morphologically recognizable as ENB, which had some but not all the criteria required to be classified as grade IV and could not be classified as pure grade III. In the current study, cellular pleomorphism, necrosis, and brisk mitotic activity, override nested architecture, and the presence of neurofibrillary matrix or rosettes. The Hyams grading scheme, which covered work predating the first description of SNUC by nearly 10 years, captures the spectrum of ENB maturation. Several groups have asserted that grade III and predominantly grade IV ENBs are in fact SNUCs [18] [19] [20] . Of note, the smear pattern of SNUC (i.e., hypercellularity, prominent necrosis, pyknosis, high nuclear:cytoplasmic ratio) mirrors closely the findings for a series of high-grade ENBs [18] . A 44-patient series from the Institut Gustave Roussy depicted low-and high-grade ENBs with distinct patterns at presentation and relapse: high-grade ENB was associated with T4 stage, frequent lymph node involvement, unresectability, and leptomeningeal metastasis, whereas low-grade ENB was associated with late locoregional recurrence) [21] . In the UCSF series of 20 ENB cases, Kaur et al. demonstrated that the Hyams criteria was the best way of predict prognosis and selecting patients for adjuvant therapy. In that series, the 5-and 10-year survival rates were 86 % for patients with low-grade ENB and 56 and 28 % for patients with high-grade ENB, respectively [22] . However, in their series all of these cases irrespective of histologic grade were high stage (stage C).
The variability of the results from this series highlight that a centralized pathology review would benefit our understanding of ENB. The published studies and the SEER case series based on tumor grade support a bias toward low-grade ENB, but there is also compelling literature demonstrating that low-and high-grade tumors are evenly distributed and that do not affect the outcome. Molecular and genetic evaluation should be added in the future to the diagnostic workup of tumors in order to refine Fig. 7 Age cutoff of 65 years reliably predicted OS the ability to discriminate poorly differentiated/high-grade ENB from other high-grade undifferentiated neoplasms [23] .
Conclusions and Remarks
Histological grading reached statistical significance, while there was no significance among Kadish-Morita stages in predicting outcome. Understanding of ENB tumor biology continues to evolve and will likely facilitate the development of improved treatment strategies for this disease. Increasingly sophisticated pathological assessments and the elucidation of molecular markers in ENB could transform the clinical management of these tumors. The identification of molecular abnormalities underlying ENB and those responsible for carcinogenesis is critical to the development of specific targeted therapies and the design of clinical trials. Because of the rarity of this entity, it is difficult for a single institution to accrue large numbers of patients. For this reason, multi-institutional and international collaboration will be necessary in collecting data prospectively and retrospectively and in reporting outcomes in a uniform manner using a common database.
